Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors Journal Article
| Authors: | Routy, B.; Le Chatelier, E.; Derosa, L.; Duong, C. P. M.; Alou, M. T.; Daillère, R.; Fluckiger, A.; Messaoudene, M.; Rauber, C.; Roberti, M. P.; Fidelle, M.; Flament, C.; Poirier-Colame, V.; Opolon, P.; Klein, C.; Iribarren, K.; Mondragón, L.; Jacquelot, N.; Qu, B.; Ferrere, G.; Clémenson, C.; Mezquita, L.; Masip, J. R.; Naltet, C.; Brosseau, S.; Kaderbhai, C.; Richard, C.; Rizvi, H.; Levenez, F.; Galleron, N.; Quinquis, B.; Pons, N.; Ryffel, B.; Minard-Colin, V.; Gonin, P.; Soria, J. C.; Deutsch, E.; Loriot, Y.; Ghiringhelli, F.; Zalcman, G.; Goldwasser, F.; Escudier, B.; Hellmann, M. D.; Eggermont, A.; Raoult, D.; Albiges, L.; Kroemer, G.; Zitvogel, L. |
| Article Title: | Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors |
| Abstract: | Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients.We found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition. Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer. Fecal microbiota transplantation (FMT) from cancer patients who responded to ICIs into germ-free or antibiotic-treated mice ameliorated the antitumor effects of PD-1 blockade, whereas FMT from nonresponding patients failed to do so. Metagenomics of patient stool samples at diagnosis revealed correlations between clinical responses to ICIs and the relative abundance of Akkermansia muciniphila. Oral supplementation with A. muciniphila after FMTwith nonresponder feces restored the efficacy of PD-1 blockade in an interleukin-12-dependent manner by increasing the recruitment of CCR9+CXCR3+CD4+ T lymphocytes into mouse tumor beds. |
| Keywords: | controlled study; antibiotic agent; advanced cancer; drug efficacy; nonhuman; mouse; mus; cancer immunotherapy; animal experiment; animal model; protein; inhibitor; drug response; genomics; cd4 lymphocyte count; tumor; intestine flora; epithelium tumor; feces; interleukin 12; feces analysis; microorganism; supplementation; programmed death 1 receptor; chemokine receptor ccr9; chemokine receptor cxcr3; microbial community; digestive system; metagenomics; cancer; priority journal; article; fecal microbiota transplantation; relative abundance; akkermansia muciniphila |
| Journal Title: | Science |
| Volume: | 359 |
| Issue: | 6371 |
| ISSN: | 0036-8075 |
| Publisher: | American Association for the Advancement of Science |
| Date Published: | 2018-01-05 |
| Start Page: | 91 |
| End Page: | 97 |
| Language: | English |
| DOI: | 10.1126/science.aan3706 |
| PROVIDER: | scopus |
| PUBMED: | 29097494 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 6 February 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work